Kryxana Injection (200mg), which contains the active ingredient Ribociclib, is a targeted therapy used primarily in the treatment of certain types of breast cancer, particularly hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR-positive, HER2-negative) breast cancer. This medication is classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor, which works by interfering with the cancer cell cycle, thereby inhibiting the proliferation of cancer cells. Kryxana Injection is typically administered in combination with an aromatase inhibitor or tamoxifen in postmenopausal women, enhancing the effectiveness of these hormonal therapies. The composition of Kryxana Injection includes Ribociclib as the active ingredient, along with various excipients that aid in the drug’s stability and delivery. This injection is a vital option for patients seeking to manage their breast cancer effectively, providing a means to improve outcomes and quality of life.